ArticleAntimicrobial agents and chemotherapy2017
Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis.Annals of clinical microbiology and antimicrobials · 2020Pooled it
- Emulating the MERINO randomised control trial using data from an observational cohort and trial of rapid diagnostic (BSI-FOO).PloS one · 2022Trial
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistantbioRxiv : the preprint server for biology · 2026Article
- Antibiotic stewardship in hematological patients with Escherichia coli and Klebsiella pneumoniae bloodstream infections: evaluating short-course and carbapenem-sparing strategies.Annals of clinical microbiology and antimicrobials · 2025Article
- Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies.Infection and drug resistance · 2025Review
- No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study.Microbiology spectrum · 2024Observational
- Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.Antibiotics (Basel, Switzerland) · 2024Article
- Article
- Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.Antibiotics (Basel, Switzerland) · 2021Review
- Multidrug resistant bacteremia in hematopoietic stem cell transplant recipients.La Tunisie medicale · 2021Article
- An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused byInfection and drug resistance · 2021Article
- Carbapenem-Sparing Strategies for ESBL Producers: When and How.Antibiotics (Basel, Switzerland) · 2020Review
- Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment.Mediterranean journal of hematology and infectious diseases · 2020Review
- Update on the management of febrile neutropenia in hematologic patients.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-ProducingAntimicrobial agents and chemotherapy · 2019Article
- Article
- Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producingAntimicrobial resistance and infection control · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 18 institutions in 9 countries.
Carlota GudiolInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain cgudiol@iconcologia.net.
Cristina Royo-CebrecosInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
Edson AbdalaInstituto do Câncer do Estado de São Paulo, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Murat AkovaHacettepe University School of Medicine, Ankara, Turkey.
Rocío ÁlvarezClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
Guillermo Maestro-de la CalleInfectious Diseases Unit, Instituto de Investigación Hospital 12 de Octubre (i+12), 12 de Octubre University Hospital, School of Medicine, Universidad Complutense, Madrid, Spain.
Angela CanoReina Sofía University Hospital-IMIBIC-UCO, Córdoba, Spain.
Carlos CerveraUniversity Hospital of Alberta, Alberta, Canada.
Wanessa T ClementeDigestive Transplant Service, Hospital das Clínicas, Universidade Federal Minas Gerais, Belo Horizonte, Brazil.
Pilar Martín-DávilaInfectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain.
Alison FreifeldInternal Medicine, Infectious Diseases Section, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Lucía GómezInternal Medicine, University Hospital Mútua de Terrassa, Barcelona, Spain.
Thomas GottliebDepartment of Microbiology & Infectious Diseases, Concord Hospital, Concord, NSW, Australia.
Mercè GurguíInfectious Diseases Unit, Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Fabián HerreraInfectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
Adriana ManzurInfectious Diseases, Hospital Rawson, San Juan, Argentina.
Georg MaschmeyerDepartment of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, Berlin, Germany.
Yolanda MeijeInfectious Disease Unit, Internal Medicine Department, Barcelona Hospital, SCIAS, Barcelona, Spain.
Miguel MontejoInfectious Diseases Unit, Cruces University Hospital, Bilbao, Spain.
Maddalena PeghinInfectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy.
Jesús Rodríguez-BañoClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospitals Virgen Macarena and Virgen del Rocío-IBiS, Department of Medicine, University of Seville, Seville, Spain.
Isabel Ruiz-CampsInfectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Teresa C SukiennikHospital Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.
Cristian TebeStatistics Advisory Service, Institute of Biomedical Research of Bellvitge, Rovira i Virgili University, Tarragona, Spain.
Jordi CarratalàInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
BICAR Study Group
Instituto de Salud Carlos III · ESInstitut d'Investigació Biomédica de Bellvitge · ESCentro de Educación Médica e Investigaciones Clínicas Norberto Quirno · ARConcord Repatriation General Hospital · AUHacettepe University · TRHospital das Clínicas da Universidade Federal de Minas Gerais · BRInstituto do Câncer do Estado de São Paulo · BRInstituto Maimónides de Investigación Biomédica de Córdoba · ESMSB Medical School Berlin · DEOspedale Santa Maria della Misericordia di Udine · ITRed Espanola de Investigacion en Patologia Infecciosa · ESResearch Institute Hospital 12 de Octubre · ESUniversidad de Sevilla · ESUniversitat Autònoma de Barcelona · ESUniversitat Rovira i Virgili · ESUniversity Hospital Mútua de Terrassa · ESUniversity of Alberta Hospital · CAUniversity of Nebraska Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
Indexed as
AdultAnti-Bacterial AgentsBacteremiabeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCarbapenemsCohort StudiesEnterobacteriaceaeEnterobacteriaceae InfectionsFemaleHumansMaleMiddle AgedNeutropeniaAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCarbapenemsbeta-lactam/beta-lactamase inhibitorsbloodstream infectionESBLsmortalityneutropenia
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.